šŸ”„ Latest GMP
Vishal Nirmitiā–¼ +20 Nityas Gemsā–¼ +3 SRIT Indiaā–² +48 Shah Investorā€™s Homeā–¼ +12 Acevectorā–¼ +1 German Green Steelā–¼ +14 Runway Enterprisesā–¼ +0 Orient Cablesā–² +107 R.K.Fashionā–¼ +0 TNA Solutionsā–¼ +6 Acme India Industriesā–¼ +25 Paramount Syntexā–¼ +0 Omara Venturesā–¼ +0 SJP Ultrasonicā–¼ +0 Eventionsā–¼ +0 Sollfege Smartā–¼ +0 Dove Softā–¼ +0 EverestIMS Technologiesā–² +28 Papadmalji Agroā–¼ +0 Vans Electroengineeringsā–¼ +70 Black Opal Consultantsā–² +66 Shree TNB Polymersā–¼ +0 Acme Universalā–² +11 Pind Hospitalityā–¼ +1 Shivchem Agroā–¼ +1 Dudani Retailā–¼ +1 Bench Mark Infotechā–¼ +26 Sai Urjaā–² +8 Himalayan Solarā–¼ +0 Green Asia Impexā–¼ +0
IPO 2026
SME IPO
IPO GMP
Subscription
Allotment
Listing

Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBLā€™s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipmentā€™s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipmentā€™s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipmentā€™s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM groupā€™s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 ā€“ Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, companyā€™s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ā‚¹184.81 ā‚¹154.97 ā‚¹32.10 ā‚¹251.58
2024 ā‚¹206.45 ā‚¹175.85 ā‚¹34.44 ā‚¹339.25
2025 ā‚¹322.58 ā‚¹261.43 ā‚¹28.13 ā‚¹455.49
Dec 2025 ā‚¹236.50 ā‚¹186.96 ā‚¹38.69 ā‚¹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (ā‚¹) EPS basic (ā‚¹)Ā  EPS Diluted (ā‚¹) RONW (%) P/E Ratio NAV (ā‚¹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ā‚¹214 Crores via IPO. The issue is priced at ā‚¹326 to ā‚¹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investorsā€™ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ā‚¹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ā‚¹326 to ā‚¹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ā‚¹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Jio Platforms IPO Date, Review, Price, Allotment Details

Join
Add Source
Follow

Reliance Jio Platforms IPO open date is October 21, 2026 and the IPO will close on October 23, 2026. Jio Platforms IPO is a Bookbuilding Issue. The company to raise around ā‚¹[.] crores via IPO that comprises fresh issue of ā‚¹[.] crores and offer for sale up to [.] equity shares with face value of ā‚¹10 each.

Jio Platforms IPO price band is ā‚¹1,065 to ā‚¹1,119 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Jio Platforms IPO to list on BSE, NSE on October 28, 2026. The allotment of Jio Platforms IPO date is October 26, 2026.

The company reported revenue of ā‚¹1,49,759.10 crores in 2026 against ā‚¹1,29,333.00 crores in 2025. The company reported profit of ā‚¹30,052.70 crores in 2026 against profit of ā‚¹26,120.30 crores in 2025.

Apply for an IPO
Jio Platforms IPO
IPO Details GMP Messages Review Apply or Avoid? Subscription Allotment Listing

Reliance Jio Platforms IPO Details

IPO Open DateOctober 21, 2026*
IPO Close DateOctober 23, 2026*
Face Valueā‚¹10 Per Equity Share
IPO Price Bandā‚¹1,065 to ā‚¹1,119 Per Share
Issue SizeApprox ā‚¹[.] Crores, 27,00,00,000 Equity Shares
Fresh IssueApprox ā‚¹[.] Crores, 27,00,00,000 Equity Shares
Issue TypeBook Building Issue
IPO ListingBSE, NSE
Shareholder QuotaYes
DRHP Draft ProspectusPDF
RHP Draft ProspectusPDF

Jio Platforms IPO Market Lot

The Jio Platforms IPO minimum market lot is 13 shares with ā‚¹14,547 application amount. The retail investors can apply up-to 13 lots with [.] shares of ā‚¹[.] amount.

ApplicationLot SizeSharesAmount
Retail Minimum113ā‚¹14,547
Retail Maximum––ā‚¹-
S-HNI Minimum––ā‚¹-
S-HNI Maximum––ā‚¹-
B-HNI Minimum––ā‚¹-

IPO Reservation

Investor CategoryShare Offered-% Shares
Anchor Investor– Shares-%
QIB (Ex. Anchor)– Shares50%
NII Shares Offered– Shares15%
Retail Shares Offered– Shares35%

Jio Platforms IPO Anchor Investors

Anchor Bidding Date2026
Anchor Investors ListPDF
Shares Offered[.] Shares
Anchor Size[.] Cr.
lock-in period end date 50% shares (30 Days) 2026
lock-in period end date 50% shares (90 Days) 2026

Jio Platforms IPO Dates

The Jio Platforms IPO date is October 21 and the close date is October 23. The Jio Platforms IPO allotment will be finalized on October 26 and the IPO listing on October 28.

IPO Open Date:October 21, 2026
IPO Close Date:October 23, 2026
Basis of Allotment:October 26, 2026
Refunds:October 27, 2026
Credit to Demat Account:October 27, 2026
IPO Listing Date:October 28, 2026

Promoters and Holding Pattern

The promoters of the company is Reliance Industries Ltd.

ParticularPre IPO SharesPre IPO % SharesPost IPO SharesPost IPO % Shares
Promoter and Promoter Group5,93,78,41,64566.43%5,93,78,41,64564.48%
Others*3,00,11,89,18533.57%3,27,11,89,18535.52%
Total8,93,90,30,830100%9,209,030,830100%

Objects of the Issue & Utilisation of proceeds

PurposeCrores
Prepayment, in full or in part, of certain outstanding borrowings availed by the Material Subsidiary, namely, RJIL.ā‚¹-
General Corporate Purposeā‚¹-

About Jio Platforms IPO

Founded in 2019, Jio Platforms is a leading digital service provider and a subsidiary of Reliance Industries. MyJio, JioCinema, JioSaavn, and Reliance Jio Infocomm are some of the digital service applications offered by Jio Platforms. Over the years, Jio Platforms has served over 524 million people with its advanced connectivity and digital services. Its main aim is to offer affordable internet connectivity, digital entertainment, gaming, cloud storage, smart home solutions, and AI-enabled digital services to every household.

Jio offers high-quality digital solutions at an affordable price point. Its ecosystem includes platforms such as MyJio, JioTV+, JioSaavn, JioGames, and JioAICloud. Moreover, the firm also offers services like enterprise connectivity, cloud solutions, IoT services, unified communications platforms, managed services, security solutions, and private 5G offerings serving enterprise customers, including banking, utilities, transportation, manufacturing, government, and information technology sectors.

Company Financial Report

Amount ā‚¹ in Crores

Period EndedRevenueExpensePATAssets
2024ā‚¹1,10,175.40ā‚¹81,367.40ā‚¹21,434.00ā‚¹5,39,580.40
2025ā‚¹1,29,333.00ā‚¹94,205.70ā‚¹26,120.30ā‚¹5,81,233.80
2026ā‚¹1,49,759.10ā‚¹1,09,406.00ā‚¹30,052.70ā‚¹6,15,594.00

Jio Platforms IPO Valuation – FY2026

Check Jio Platforms IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

KPIValues
ROE:-%
ROCE:10.76%
EBITDA Margin:51.91%
PAT Margin:20.46%
Debt to equity ratio: [.]
Earning Per Share (EPS):ā‚¹33.63 (Basic)
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):9.42%
Net Asset Value (NAV):ā‚¹373.66

Peer Group Comparison

CompanyEPSPE RatioRoNW %NAVIncome
Bharti Airtel Limited44.3742.2720.32244.602,10,972.80 Cr.
Vodafone Idea Limited3.214.65–(3.30)44,873.00 Cr.

IPO Lead Managers / Merchant Bankers

  • Kotak Mahindra Capital Co. Ltd.
  • Morgan Stanley India Co. Pvt. Ltd.
  • BOFA Securities India Ltd.
  • Axis Capital Ltd.
  • BNP Paribas
  • Citigroup Global Markets India Pvt. Ltd.
  • CLSA India Pvt. Ltd.
  • Dam Capital Advisors Ltd.
  • Goldman Sachs (India) Securities Pvt. Ltd.
  • HDFC Bank Ltd.
  • HSBC Securities & Capital Markets (India) Pvt. Ltd.
  • ICICI Securities Ltd.
  • IIFL Capital Services Ltd.
  • Jefferies India Pvt. Ltd.
  • JM Financial Ltd.
  • JP Morgan India Pvt. Ltd.
  • SBI Capital Markets Ltd.
  • UBS Securities India Pvt. Ltd.
  • 360 One WAM Ltd.

Company Address

Jio Platforms Ltd.
Office – 101, Saffron,
Nr. Centre Point, Panchwati 5 Rasta,
Ambawadi
Ahmedabad, Gujarat, 380006
Phone: +91 22 7967 0000
Email: jpl.investorrelations@jio.com
Website: https://www.jio.com/

IPO Registrar

Kfin Technologies Ltd.
Phone: 040-79615565
Email: jioplatforms.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/

Jio Platforms IPO FAQs

What is Reliance Jio Platforms IPO?

Reliance Jio Platforms IPO is Mainboard IPO. The company is going to raise ā‚¹[.] Crores via IPO. The issue is priced at ā‚¹1,065 to ā‚¹1,119 per equity share. The IPO is to be listed on BSE & NSE.

When Jio Platforms IPO will open for subscription?

The IPO is to open on October 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on October 23, 2026.

What is Jio Platforms IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Jio Platforms IPO?

You can apply for Jio Platforms IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

What is Jio Platforms IPO Issue Size?

Jio Platforms IPO issue size is ā‚¹[.] crores.

What is Jio Platforms IPO Price Band?

Jio Platforms IPO Price Band is ā‚¹1,065 to ā‚¹1,119.

What is Jio Platforms IPO Lot Size?

The minimum bid is [.] Shares with ā‚¹[.] amount.

What is the Jio Platforms IPO Allotment Date?

Jio Platforms IPO allotment date is October 26, 2026.

What is the Jio Platforms IPO Listing Date?

Jio Platforms IPO listing date is October 28, 2026. The IPO is to list on BSE & NSE.

Note: The Jio Platforms IPO price band and date are officially announced. The (Jio Platforms IPO grey market premium) will be added to the IPO GMP page as it will start).
Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

Add IPOWatch to your Google News feed.   google news button

6 Responses

    1. Hi

      There might be a reservation of RIL shares. You can buy 1 share, as the RHP has not been filed yet. The same will be updated according to the final update from the RHP.

      Reply

  2. Can I apply all 3 categories in this ipo or not
    1 retail category
    2 employee category
    3 shareholder category

    Please not I have RIL share since one year also I have on roll Employee of RJIL and retail category as a normal investor please let .me know

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Current Mainboard IPO

Current SME IPO

Latest IPO News

IMP LINKS

Join WhatsApp Channel